Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrIuMPH
ISRCTN65517362Phase 2Completed
- Sponsor
- EnteroBiotix
- Start
- Mar 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) and Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing EBX-102-02 with Placebo (2 arms). Primary endpoint: Incidence and type of adverse events. Started Mar 2024; status: completed.
02
Drugs
EBX-102-02
03
Conditions
irritable bowel syndrome (IBS)Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ISRCTN65517362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65517362.